Search
Alkaline Phosphatase
go.drugbank.com/drugs/DB05768InvestigationalAP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigational[A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]
Binimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalEncorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by
Faropenem medoxomil
go.drugbank.com/drugs/DB05659InvestigationalIt is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.
Thiabendazole
go.drugbank.com/drugs/DB00730ApprovedVet approvedWithdrawn2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of P...
Laronidase
go.drugbank.com/drugs/DB00090ApprovedInvestigationalHuman recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line.
Estrone
go.drugbank.com/drugs/DB00655ApprovedEstrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
Pirenzepine
go.drugbank.com/drugs/DB00670ApprovedWithdrawnIt is generally well tolerated by patients.
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnSerdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia.
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive